- Home
- AAUC vs RCUS Comparison
AAUC vs RCUS Comparison
Compare AAUC & RCUS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | AAUC | RCUS |
|---|---|---|
| Founded | N/A | 2015 |
| Country | Canada | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.8B | 3.2B |
| IPO Year | 2023 | 2018 |
Fundamental Metrics
Financial Performance| Metric | AAUC | RCUS |
|---|---|---|
| Price | $20.78 | $23.85 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 5 | 14 |
| Target Price | $29.45 | ★ $40.00 |
| AVG Volume (30 Days) | 347.5K | ★ 1.2M |
| Earning Date | 11-19-2026 | 11-03-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $247,000,000.00 |
| Revenue This Year | $29.13 | N/A |
| Revenue Next Year | $58.95 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $14.60 | $16.41 |
| 52 Week High | $32.20 | $31.74 |
Technical Indicators
Market Signals| Indicator | AAUC | RCUS |
|---|---|---|
| Relative Strength Index (RSI) | 50.58 | 34.00 |
| Support Level | $20.55 | $20.13 |
| Resistance Level | $24.69 | $23.45 |
| Average True Range (ATR) | 0.77 | 1.01 |
| MACD | 0.12 | -0.14 |
| Stochastic Oscillator | 73.40 | 16.00 |
Price Performance
Historical ComparisonAbout AAUC Allied Gold Corporation
Allied Gold Corp is a company focused on gold mining activities in Africa. Allied has three mines and several development and exploration projects in Africa, where it has operating experience. Operations are located in Cote d'Ivoire, Mali, and Ethiopia. The company expands and optimizes initiatives at existing operating mines, develops new mines, advances its exploration properties, and targets other consolidation opportunities, with a focus on Africa.
About RCUS Arcus Biosciences Inc.
Arcus Biosciences Inc is a late clinical-stage biopharmaceutical company focused on developing differentiated molecules for patients with cancer and inflammatory and autoimmune diseases. Its product pipeline includes Domvanalimab, Quemliclustat, Casdatifan, Zimberelimab, among others. The company operates in one reportable and operating segment, which is the business of developing and commercializing differentiated therapies.